Introduction to a Key Publication on Biodefense:
“Good morning/afternoon, everyone. Today, we will delve into a highly significant article published in JAMA The Journal of the American Medical Association, titled ‘Plague as a biological weapon: medical and public health management’. This comprehensive consensus statement, published on May 3, 2000, as part of Volume 283, Issue 17, pages 2281-2290, is the third article in a vital series focused on medical and public health management following the use of a biological weapon. While ResearchGate and PubMed indicate a June 2000 publication for this article, the internal journal pages specify May 3, 2000.
The article was developed by the Working Group on Civilian Biodefense, a multidisciplinary group comprising 25 representatives from major academic medical centers, research institutions, government bodies, military organizations, public health agencies, and emergency management institutions. Notably, its extensive list of 19 authors includes prominent experts such as Thomas V. Inglesby, David T. Dennis (from the Centers for Disease Control and Prevention), Donald A. Henderson, and John G. Bartlett (from Johns Hopkins Medicine).
The primary objective of this working group was to develop consensus-based recommendations for medical and public health professionals concerning the measures to be taken if plague were used as a biological weapon against a civilian population. This topic is of great concern due to the global availability of Yersinia pestis (the causative agent of plague), the capacity for its mass production and aerosol dissemination, the difficulty in preventing such activities, the high fatality rate of pneumonic plague, and its potential for secondary spread during an epidemic. Y. pestis is identified as one of the “Critical Biological Agents” by the Centers for Disease Control and Prevention (CDC).
Methodology and Scope: The consensus statement was formulated through a rigorous process. Researchers extensively searched MEDLINE databases from January 1966 to January 2000 using relevant Medical Subject Headings such as “plague,” “Yersinia pestis,” “biological weapon,” “biological terrorism,” and “biowarfare”. This was supplemented by a review of bibliographies and the identification of unpublished references and expert sources by the participants. Multiple drafts of the document were reviewed and revised by the working group in October 1998 and May 1999, ensuring that the final recommendations were supported by all members and incorporated all relevant evidence.
Key Insights and Recommendations:
- Differing Epidemiology: The article emphasizes that plague following a biological weapon attack would differ substantially from naturally occurring infection. Intentional dissemination would most likely occur via an aerosol of Y. pestis, leading to primary pneumonic plague.
- Clinical Presentation: Following aerosol exposure, symptoms such as fever, cough, chest pain, and hemoptysis would typically appear within 1 to 6 days. The disease would progress rapidly in 2 to 4 days after symptom onset, leading to septic shock with high mortality without early treatment. Prominent gastrointestinal symptoms like nausea, vomiting, abdominal pain, and diarrhea might also be present.
- Diagnosis Challenges: Early diagnosis is critical but challenging due to the rarity of plague and its initial clinical similarity to other severe respiratory illnesses. The sudden appearance of numerous previously healthy patients with severe pneumonia and sepsis, particularly with hemoptysis, should strongly suggest pneumonic plague or inhalational anthrax. There are no widely available rapid diagnostic tests for plague.
- Antibiotic Therapy: The working group provides consensus-based recommendations for treatment, acknowledging the lack of published human trials.
- For contained casualty settings (modest numbers of patients), parenteral streptomycin or gentamicin are the preferred choices.
- For mass casualty settings (where parenteral therapy may be impractical) or for postexposure prophylaxis, oral doxycycline or ciprofloxacin are recommended.
- Treatment should generally be continued for 10 days, and prophylaxis for 7 days. Delaying therapy significantly decreases survival.
- Special Populations: Specific recommendations are provided for children, pregnant women, and breastfeeding women, balancing efficacy against potential risks associated with antibiotics. For example, doxycycline is recommended for children in mass casualty settings despite potential tooth discoloration, as the benefits outweigh the risks of pneumonic plague.
- Infection Control: Person-to-person transmission of pneumonic plague occurs via respiratory droplets. The working group recommends respiratory droplet precautions and wearing a surgical mask for those in close contact with untreated patients. Patients should remain isolated for at least 48 hours of antibiotic therapy and until clinical improvement occurs.
- Environmental Decontamination: The article states that environmental decontamination is not necessary following an aerosol release of plague. Y. pestis does not form spores and is highly sensitive to environmental conditions like sunlight and heat, meaning it does not survive long outside a host. The aerosol would have dissipated long before the first cases appear.
This article serves as a critical resource for understanding and preparing for the potential threat of plague as a biological weapon, outlining the necessary medical and public health responses based on the best available evidence at the time of its publication.”
APA Reference:
Inglesby, T. V., Dennis, D. T., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Friedlander, A. M., Hauer, J., Koerner, J. F., Layton, M., McDade, J., Osterholm, M. T., O’Toole, T., Parker, G., Perl, T. M., Russell, P. K., Schoch-Spana, M., & Tonat, K. (2000). Plague as a biological weapon: medical and public health management. JAMA, 283(17), 2281–2290.
